Ribivirin
Executive Summary
Clinical trials on 200 patients (in the U.S.) and 500 (internationally) are "underway or are about to start," Viratek reports. Studies, which were okayed when FDA lifted the clinical hold on the product, are aimed at lymphadenopathy syndrome (LAS) patients. Sales of ribavirin for RSV (respiratory syncytial virus) declined sharply in 1987: down to $1.4 mil. from $10.9 mil. the year before.
Clinical trials on 200 patients (in the U.S.) and 500
(internationally) are "underway or are about to start," Viratek
reports. Studies, which were okayed when FDA lifted the clinical
hold on the product, are aimed at lymphadenopathy syndrome (LAS)
patients. Sales of ribavirin for RSV (respiratory syncytial virus)
declined sharply in 1987: down to $1.4 mil. from $10.9 mil. the
year before. |